Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Accuracy and Errors in Hypothesis Testing01:13

Accuracy and Errors in Hypothesis Testing

199
Hypothesis testing is a fundamental statistical tool that begins with the assumption that the null hypothesis H0 is true. During this process, two types of errors can occur: Type I and Type II. A Type I error refers to the incorrect rejection of a true null hypothesis, while a Type II error involves the failure to reject a false null hypothesis.
In hypothesis testing, the probability of making a Type I error, denoted as α, is commonly set at 0.05. This significance level indicates a 5%...
199
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

126
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
126
Errors In Hypothesis Tests01:14

Errors In Hypothesis Tests

4.2K
When performing a hypothesis test, there are four possible outcomes depending on the actual truth (or falseness) of the null hypothesis and the decision to reject or not.
4.2K
Hazard Ratio01:12

Hazard Ratio

121
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
121
Bonferroni Test01:10

Bonferroni Test

2.7K
The Bonferroni test is a statistical test named after Carlo Emilio Bonferroni, an Italian mathematician best known for Bonferroni inequalities. This statistical test is a type of multiple comparison test to determine which means are different than the rest. Bonferroni test can minimize the Type 1 error by reducing the significance level alpha, which otherwise increases with sample pairs.
The means of different samples are first paired in all possible combinations.
The null hypothesis of the...
2.7K
Comparing Experimental Results: Student's t-Test01:09

Comparing Experimental Results: Student's t-Test

1.6K
The t-test is a statistical method used to compare the sample mean with a population mean or compare two means from two data sets. The test statistic is calculated from the standard deviation, mean, and number of measurements in the data set at a selected confidence interval and then compared to a table of critical values at this confidence level. If the test statistic is smaller than the critical value, the null hypothesis is accepted. In this case, we state that the difference between the...
1.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Comparing Methods to Assess Treatment Effect Heterogeneity in General Parametric Regression Models.

Statistics in medicine·2026
Same author

Overview and Practical Recommendations on Using Shapley Values for Identifying Predictive Biomarkers via CATE Modeling.

Statistics in medicine·2026
Same author

Using Individualized Treatment Effects to Assess Treatment Effect Heterogeneity.

Statistics in medicine·2025
Same author

WATCH: A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors.

Pharmaceutical statistics·2024
Same author

A framework for longitudinal latent factor modelling of treatment response in clinical trials with applications to Psoriatic Arthritis and Rheumatoid Arthritis.

Journal of biomedical informatics·2024
Same author

Editorial for the special collection "Towards neutral comparison studies in methodological research".

Biometrical journal. Biometrische Zeitschrift·2024

相关实验视频

Updated: Jul 2, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.5K

所有闪闪发光的都不是黄金:I型错误受控变量从临床试验数据中选择

Manuela R Zimmermann1, Mark Baillie1, Matthias Kormaksson1

  • 1Novartis Pharma AG, Basel, Switzerland.

Clinical pharmacology and therapeutics
|February 29, 2024
PubMed
概括

淘汰框架从临床试验数据中提供可靠的变量选择,控制错误发现. 一种新方法提高了生物标志物发现的效率和错误控制,提高了研究可重复性.

科学领域:

  • 生物统计学 生物统计学
  • 临床研究方法论 临床研究方法论
  • 翻译医学是一种翻译医学.

背景情况:

  • 临床试验数据为二级研究提供了丰富的潜力,包括生物标志物发现和预后建模.
  • 临床环境中的探索性分析通常由于多次比较而存在高错误发现率 (I型错误).
  • 现有的变量选择方法可能无法充分控制这些错误,导致不清楚的不确定性估计.

研究的目的:

  • 对临床试验数据中可靠变量选择的淘汰框架进行审查和扩展.
  • 引入一种新的仿制生成方法,解决混合数据设置和临床开发中的局限性.
  • 提高识别预后生物标志物和治疗疗效预测者的可靠性和效率.

主要方法:

  • 复制框架的审查,这是一种模型不可知的方法,用于可变选择,并有保证的I型错误控制.
  • 开发和应用一种针对临床数据和混合数据类型优化的新型仿制生成方法.
  • 模拟研究评估I型错误控制,计算效率和生物标志物选择性能.
  • 经验验证使用临床试验中的数据来验证牛皮关节炎患者的C-反应性蛋白水平.

主要成果:

  • 新的仿制生成方法为I型错误控制提供了更严格的界限.
  • 在混合数据设置中,计算效率 (数量级) 得到了显著的改进.

更多相关视频

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

509

相关实验视频

Last Updated: Jul 2, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.5K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

509
  • 扩展框架的表现与现有方法在识别预后生物标志物的表现相似.
  • 在四个临床试验中成功地在牛皮关节炎患者中识别C反应性蛋白水平的生物标志物.
  • 结论:

    • 增强的淘汰框架增加了从临床试验数据中选择变量的可访问性.
    • 这种方法有助于通过确保可靠的生物标志物发现来缓解可复制性危机.
    • 该方法减少了不必要的研究,患者负担和临床开发中的相关成本.